A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19
- Conditions
- COVID-19
- Interventions
- Biological: IBI314(low dose)Other: PlaceboBiological: IBI314(high dose)Biological: IBI314(medium dose)
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT05172141
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: IBI 389 InjectionDrug: IBI 308 injection
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT05164458
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chendu, Sichuan, China
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
- Conditions
- COVID-19
- Interventions
- Other: PlaceboBiological: IBI314
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 248
- Registration Number
- NCT05162365
- Locations
- 🇺🇸
Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States
🇺🇸Luminous Clinical Research LLC - South Florida Urgent Care - Infectious Diseases, Pembroke Pines, Florida, United States
🇺🇸Temple University Health System - Temple Lung Center, Philadelphia, Pennsylvania, United States
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT05148442
- Locations
- 🇨🇳
The first affiliated hospital of soochow university, Suzhou, Jiangsu, China
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05119998
- Locations
- 🇨🇳
Shandong Province Cancer Hospital, Jinan, Shandong, China
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
- Conditions
- NSCLC (Non-small-cell Lung Cancer)
- Interventions
- Drug: IBI310
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05118334
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT05116462
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05088967
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: IBI 360 InjectionDrug: IBI 360 Injection Sintilimab
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05043298
- Locations
- 🇨🇳
Innovent Biologics (suzhou) Co. , Ltd., Suzhou, Jiangsu, China
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05039658
- Locations
- 🇨🇳
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China